Bank Of New York Mellon Corp Keros Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$39.45 - $51.77 $3.71 Million - $4.86 Million	93,927 New	93,927 $4.51 Million
Q3 2022 Nov 14, 2022	BUY	$27.8 - $40.12 $771,283 - $1.11 Million	27,744 Added 59.32%	74,517 $2.8 Million
Q2 2022 Aug 15, 2022	BUY	$26.03 - $67.04 $8,355 - $21,519	321 Added 0.69%	46,773 $1.29 Million
Q1 2022 May 11, 2022	BUY	$42.12 - $59.36 $6,402 - $9,022	152 Added 0.33%	46,452 $2.53 Million
Q4 2021 Feb 11, 2022	BUY	$36.95 - $62.89 $123,597 - $210,367	3,345 Added 7.79%	46,300 $2.71 Million
Q3 2021 Nov 12, 2021	BUY	$29.27 - $43.71 $134,495 - $200,847	4,595 Added 11.98%	42,955 $1.7 Million
Q2 2021 Aug 11, 2021	SELL	$42.4 - $70.11 $185,245 - $306,310	-4,369 Reduced 10.22%	38,360 $1.63 Million
Q1 2021 May 13, 2021	SELL	$54.0 - $75.28 $6,696 - $9,334	-124 Reduced 0.29%	42,729 $2.63 Million
Q4 2020 Feb 09, 2021	BUY	$36.0 - $82.74 $890,928 - $2.05 Million	24,748 Added 136.69%	42,853 $3.02 Million
Q3 2020 Nov 12, 2020	SELL	$27.04 - $62.21 $2,298 - $5,287	-85 Reduced 0.47%	18,105 $698,000
Q2 2020 Aug 12, 2020	BUY	$20.08 - $40.39 $365,255 - $734,694	18,190 New	18,190 $682,000

174

30.3M

76.8K

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.46B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.